Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy-induced peripheral neurotoxicity: Systematic review and directions for future research.

Publisher: Wiley Country of Publication: United States NLM ID: 9704532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-8027 (Electronic) Linking ISSN: 10859489 NLM ISO Abbreviation: J Peripher Nerv Syst Subsets: MEDLINE

Publication: <2010->: Hoboken, NJ Wiley
Original Publication: New York, NY : Woodland Publications, c1996-

Wearable Electronic Devices* ; Antineoplastic Agents*/adverse effects ; Neurotoxicity Syndromes*/diagnosis ; Neurotoxicity Syndromes*/etiology ; Neurotoxicity Syndromes*/therapy; Humans

Chemotherapy-induced peripheral neurotoxicity (CIPN) diagnosis is largely based on patient reported outcomes. Wearables, sensors, and smart devices may potentially provide early detection and monitoring of CIPN. We systematically reviewed data on wearables, sensors, and smart devices to detect and/or monitor signs and symptoms of CIPN. Moreover, we provide directions and recommendations for future studies. A literature search using PubMed/MEDLINE, Web of Science, IEEE Xplore, and CINHAL databases was conducted from database inception until March 2021. The search was further updated in July 2022 to ensure currency of results. A total of 1885 records were title-abstract screened, 33 full texts were assessed, and 16 were included. The retrieved papers were heterogeneous in terms of study design, sample size, CIPN severity, chemotherapy agents, type of wearable/sensor/device applied, parameters of interest, and purpose. Data are promising and provide preliminary evidence on wearables, sensors, and smart devices for CIPN detection and monitoring. There are several issues and knowledge gaps that should be addressed. We propose a framework for future studies.
(© 2022 Peripheral Nerve Society.)

Cavaletti G, Alberti P, Argyriou AA, et al. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Peripher Nerv Syst. 2019;24(suppl 2):S6-S12. doi:10.1111/jns.12337.
Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A, Argyriou AA. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(suppl 2):S40-S51. doi:10.1111/jns.12336.
Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(suppl 2):S26-S39. doi:10.1111/jns.12335.
Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419-437. doi:10.3322/caac.21204.
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi:10.1016/j.pain.2014.09.020.
Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699-2707. doi:10.1200/JCO.2013.49.1514.
Hertz DL, Childs DS, Park SB, et al. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021;99:102241. doi:10.1016/j.ctrv.2021.102241.
Gewandter JS, Kleckner AS, Marshall JH, et al. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer. 2020;28(6):2553-2562. doi:10.1007/s00520-019-05063-x.
Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604-2612. doi:10.1200/JCO.2016.71.3552.
Argyriou AA, Bruna J, Anastopoulou GG, Velasco R, Litsardopoulos P, Kalofonos HP. Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. Support Care Cancer. 2020;28(4):1991-1995. doi:10.1007/s00520-019-05023-5.
Argyriou AA, Bruna J, Park SB, Cavaletti G. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Rev Neurother. 2020;20(10):1005-1016. doi:10.1080/14737175.2020.1796639.
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399.
Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 2020;43(3):E172-E185. doi:10.1097/NCC.0000000000000801.
Park SB, Tamburin S, Schenone A, et al. Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: systematic review and consensus expert opinion. Expert Rev Neurother. 2022;22(1):65-76. doi:10.1080/14737175.2022.2018300.
Tamburin S, Park SB, Schenone A, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022;171:103575. doi:10.1016/j.critrevonc.2021.103575.
Eckhoff L, Knoop A, Jensen MB, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292-300. doi:10.1016/j.ejca.2014.11.024.
Pabst L, Velten M, Fischbach C, et al. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer. Breast J. 2020;26(12):2376-2382. doi:10.1111/tbj.14123.
Argyriou AA, Park SB, Islam B, et al. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry. 2019;90(12):1361-1369. doi:10.1136/jnnp-2019-320969.
Salgado TM, Quinn CS, Krumbach EK, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer. 2020;28(9):4163-4172. doi:10.1007/s00520-019-05254-6.
Mantovani E, Zucchella C, Bottiroli S, et al. Telemedicine and virtual reality for cognitive rehabilitation: a roadmap for the COVID-19 pandemic. Front Neurol. 2020;11:926. Published 2020 Sep 15. doi:10.3389/fneur.2020.00926.
Corrà MF, Warmerdam E, Vila-Chã N, Maetzler W, Maia L. Wearable health technology to quantify the functional impact of peripheral neuropathy on mobility in Parkinson's disease: a systematic review. Sensors. 2020;20(22):6627. doi:10.3390/s20226627.
Demrozi F, Bacchin R, Tamburin S, Cristani M, Pravadelli G. Toward a wearable system for predicting freezing of gait in people affected by Parkinson's disease. IEEE J Biomed Health Inform. 2020;24(9):2444-2451. doi:10.1109/JBHI.2019.2952618.
Omberg L, Chaibub Neto E, Perumal TM, et al. Remote smartphone monitoring of Parkinson's disease and individual response to therapy. Nat Biotechnol. 2022;40(4):480-487. doi:10.1038/s41587-021-00974-9.
Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018;320(2):146-155. doi:10.1001/jama.2018.8102.
Bayoumy K, Gaber M, Elshafeey A, et al. Smart wearable devices in cardiovascular care: where we are and how to move forward. Nat Rev Cardiol. 2021;18(8):581-599. doi:10.1038/s41569-021-00522-7.
Golledge J, Fernando M, Lazzarini P, Najafi B, Armstrong DG. The potential role of sensors, wearables and telehealth in the remote management of diabetes-related foot disease. Sensors. 2020;20(16):4527. doi:10.3390/s20164527.
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
Paez A. Grey literature: an important resource in systematic reviews. J Evid Based Med. 2017. doi:10.1111/jebm.12265.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi:10.1186/s13643-016-0384-4.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536. doi:10.7326/0003-4819-155-8-201110180-00009.
Jacobs PG, Hanaway P, Leitschuh J, et al. Design and evaluation of a portable smart-phone based peripheral neuropathy test platform. Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:1-4. doi:10.1109/EMBC.2018.8513100.
Fino PC, Horak FB, El-Gohary M, et al. Postural sway, falls, and self-reported neuropathy in aging female cancer survivors. Gait Posture. 2019;69:136-142. doi:10.1016/j.gaitpost.2019.01.025.
Zahiri M, Chen KM, Zhou H, et al. Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults - toward an early diagnosis of CIPN. J Geriatr Oncol. 2019;10(6):960-967. doi:10.1016/j.jgo.2019.01.010.
Chen CS, Kim J, Garg N, et al. Chemotherapy-induced peripheral neuropathy detection via a smartphone app: cross-sectional pilot study. JMIR Mhealth Uhealth. 2021;9(7):e27502. doi:10.2196/27502.
Sada YH, Poursina O, Zhou H, Workeneh BT, Maddali SV, Najafi B. Harnessing digital health to objectively assess cancer-related fatigue: the impact of fatigue on mobility performance. PLoS One. 2021;16(2):e0246101. doi:10.1371/journal.pone.0246101.
Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B. Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Gerontology. 2016;62(5):553-563. doi:10.1159/000442253.
Matsuoka A, Mitsuma A, Maeda O, et al. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device. Cancer Sci. 2016;107(10):1453-1457. doi:10.1111/cas.13010.
Jokimäki A, Iivanainen S, Mikkonen R, Mika K, Koivunen J. Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device. Cancer Rep. 2022;e1677. doi:10.1002/cnr2.1677.
Sharma S, Venkitaraman R, Vas PR, Rayman G. Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction. Brain Behav. 2015;5(7):e00354. doi:10.1002/brb3.354.
Saad M, Psimaras D, Tafani C, et al. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy. J Neurooncol. 2016;127(2):373-380. doi:10.1007/s11060-015-2049-x.
Allegra A, Rizzo V, Innao V, et al. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. Arch Med Sci. 2021;18(3):696-703. Published 2021 Jan 11. doi:10.5114/aoms/114269.
Griffith KA, Couture DJ, Zhu S, et al. Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer. 2014;22(5):1161-1169. doi:10.1007/s00520-013-2068-0.
Sato J, Mori M, Nihei S, Takeuchi S, Kashiwaba M, Kudo K. Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision®), a pilot study. J Pharm Health Care Sci. 2017;3:21. doi:10.1186/s40780-017-0089-4.
Yoshida Y, Satoh A, Yamada T, et al. The relationship between evaluation methods for chemotherapy-induced peripheral neuropathy. Sci Rep. 2019;9(1):20361. doi:10.1038/s41598-019-56969-9.
Saito M, Odajima S, Yokomizo R, et al. A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100®. Asia Pac J Clin Oncol. 2020;16(1):80-85. doi:10.1111/ajco.13293.
Marstrand SD, Buch-Larsen K, Andersson M, Jensen LT, Schwarz P. Vibration perception threshold and heart rate variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study. Cancer Treat Res Commun. 2021;28:100426. doi:10.1016/j.ctarc.2021.100426.
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. doi:10.3390/ijms20061451.
Wang AB, Housley SN, Flores AM, Kircher SM, Perreault EJ, Cope TC. A review of movement disorders in chemotherapy-induced neurotoxicity. J Neuroeng Rehabil. 2021;18(1):16. doi:10.1186/s12984-021-00818-2.
Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012;20(4):877-881. doi:10.1007/s00520-011-1336-0.
Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017;17(6):47. doi:10.1007/s11910-017-0757-7.
Beauchamp UL, Pappot H, Hollander-Mieritz C. The use of wearables in clinical trials during cancer treatment: systematic review. JMIR Mhealth Uhealth. 2020;8(11):e22006. doi:10.2196/22006.
Rawson TM, Gowers SAN, Freeman DME, et al. Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. Lancet Digit Health. 2019;1(7):e335-e343. doi:10.1016/S2589-7500(19)30131-1.

Keywords: chemotherapy-induced peripheral neurotoxicity; evidence-based medicine; information and communication technology; sensors; telemedicine

0 (Antineoplastic Agents)

Date Created: 20221013 Date Completed: 20221205 Latest Revision: 20221222

20240829

10.1111/jns.12518

36224713